Inclusion Criteria:  males or females of any race>(=)18 years age. Histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are without standard treatment options. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Life expectancy>(=)12 weeks. Adequate organ and marrow function. Measurable or evaluable disease.  Exclusion Criteria:  Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose. Toxicities from previous anti-cancer therapy that have not recovered as required. Brain metastatic disease, spinal cord compression, or leptomeningeal carcinomatosis. 4.Active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV):  5.Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while in this study or within 3 months after the last dose.  6.Male subjects who plan to father a child while enrolled in the study or within 3 months after the last dose.  7.Received prior treatment with a PIM kinase inhibitor.